AI Quick Summary

AB2 Bio secures USD 650 million partnership for rare disease therapy AB2 Bio Ltd based at EPFL Innovation Park I site of Switzerland Innovation Park West EPFL has signed a major licensing agreement with Japan’s Nippon Shinyaku for Tadekinig alfa, a novel therapy targeting a rare hyperinflammatory syndrome. With up to USD 650 million in milestone payments, this partnership accelerates the treatment’s path to market, promising life-changing solutions for young patients. Recognized for its breakthrough potential, Tadekinig alfa holds U.S. and European Orphan Drug Designations, setting a benchmark in biotech innovation.Full article : here

Post Metadata

• Author: Switzerland Innovation Digital
• Published Date: 1/29/2025 8:34:12 AM
• Modified Date: 1/29/2025 8:34:12 AM

Post Description

AB2 Bio secures USD 650 million partnership for rare disease therapy

AB2 Bio Ltd based at EPFL Innovation Park I site of Switzerland Innovation Park West EPFL has signed a major licensing agreement with Japan’s Nippon Shinyaku for Tadekinig alfa, a novel therapy targeting a rare hyperinflammatory syndrome.

With up to USD 650 million in milestone payments, this partnership accelerates the treatment’s path to market, promising life-changing solutions for young patients. Recognized for its breakthrough potential, Tadekinig alfa holds U.S. and European Orphan Drug Designations, setting a benchmark in biotech innovation.

Full article : here